Katie Paxton-Fear is neurodiverse (‘autistic’, she says). It’s a common, but not causal, condition among hackers. Autism ...

Researchers are trying to understand why some wild species do better than others over time, as the environment changes.

The Center for Clinical Standards and Quality at CMS was “staring down a crisis” when Lee Fleisher took charge of the center ...

The Lung Cancer Research Foundation® (LCRF) recently awarded five new research grants in the following areas: three LCRF ...

NeoCurrency, a leading global provider of digital rewards, incentives and payout solutions, is celebrating its 10th anniversary in 2026. The company has achieved a decade of helping brands, ...

Gilgamesh Pharma, a clinical-stage neuroscience company focused on transforming psychiatric treatment, today announced positive topline results from its Phase 2a study of blixeprodil (GM-1020).

The clinical-stage biopharmaceutical company announced that its Phase 1 trial showed significant responses in difficult-to-treat pediatric cancers, including two Complete Metabolic Responses in ...

Investing.com -- Alkermes Plc (NASDAQ:ALKS) stock rose 3.4% in premarket trade Tuesday after the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to the company’s ...

GSK has secured approval in Japan for Exdensur (depemokimab), the country’s first ultra-long-acting biologic for severe asthma and chronic rhinosinusitis with nasal polyps. Approved by Japan’s ...